New collaboration between Foundation Medicine and H3 aims to develop precision cancer therapies.

Foundation Medicine and H3 Biomedicine announced a multi-year collaboration working on the discovery and development of precision therapies for cancer.

Foundation Medicine will contribute through 35,000 genomic profiles in their FoundationCORE database, while H3 bring their drug discovery engine and computational platform. The aim is to identify potential drug targets based on the genetic profile of an individual cancer. It is hoped that this will increase efficacy and shorten the time and cost of clinical development.

“Large-scale genomic data sets are the key to identifying actionable targets and addressing the multitude of difficult-to-treat cancers,” said Markus Warmuth, M.D., president and chief executive officer of H3 Biomedicine. “More than ever before, we in cancer drug development have the benefit of an ever-growing arsenal of genomic information including publicly available data sets that inform validation of targets, development of therapies and translation from bench to bedside. In this regard, we believe Foundation Medicine offers one of the most comprehensive cancer genomics knowledgebases available. This collaborative effort will further empower our state-of-the-art discovery engines to deliver novel first-in-class medicines and improve our clinical development strategies by accessing a wealth of clinically annotated, genomic information at least in part derived from later-stage and metastatic cancers.”

The full press release can be found here.